This article is brought to you in partnership with Lannett CDMO
The pharmaceutical industry has a tech transfer problem. Industry executives consistently cite timeline delays, cost overruns, and quality compromises as major pain points in tech transfer that could have been prevented with a different approach.
The most reliable, cost-efficient tech transfers don’t begin at the point of transfer. They begin much earlier, with decisions about process robustness, data integrity, and alignment around the end goal: commercial-ready manufacturing.
Organizations that treat tech transfer as a box to be checked experience delays, rework, and escalating costs. Conversely, those that treat it as a core operational discipline build products that scale with fewer surprises and far greater predictability.
Tech Transfer as a Strategic Capability, Not a Project Milestone
A well-executed tech transfer includes stress-testing assumptions, refining parameters, and ensuring reproducibility across commercial volumes. That mindset of capability-building rather than capability-checking is what enables smoother transitions from development to commercialization, even when requirements shift midstream.
“The question you must consider is not just whether a CDMO has the exact capabilities you need today,” says Joseph ‘Joe’ Bomba, Director of CDMO Strategic Partnerships at Lannett CDMO. “But whether they have the infrastructure, expertise, and commitment to close capability gaps quickly. We’ve proven repeatedly that the right partner can build specialized solutions in months, not years.”
The Timeline Paradox: Why Most Tech Transfers Slip
Despite careful planning, tech transfer timelines frequently slip. The reasons are often misunderstood.
Strong project management, transparent communication, and disciplined documentation matter as much as technical expertise. “After facilitating hundreds of tech transfers, I can tell you that timeline failures rarely stem from technical challenges,” Joe notes. “They come from misaligned expectations and poor stakeholder coordination. The CDMOs that consistently deliver on schedule are masters of communication, not just manufacturing.”
Successful CDMOs plan timelines strategically, allocate resources deliberately, and maintain constant visibility into progress, adjusting in real time without losing sight of the end goal.
Balancing Speed, Cost, and Quality
Cost-conscious tech transfer means designing smarter pathways to minimize material use, reducing unnecessary trial runs, and applying lean manufacturing principles to eliminate waste while preserving compliance and scalability.
“Real-time data analytics has transformed how we approach tech transfer optimization,” Joe explains. “What used to require multiple trial runs can now be refined continuously, cutting both timelines and material waste. But technology only works when paired with experienced human judgment.”
This combination of advanced analytics and seasoned expertise allows CDMOs to optimize faster without compromising product integrity.
The Myth of “Plug-and-Play” Tech Transfer
The idea that tech transfer is a plug-and-play exercise remains one of the most costly misconceptions in pharmaceutical manufacturing. Poorly executed transfers lead to delays, repeated validations, excess material consumption, and lost revenue.
“Adapting to complexity is what sustains momentum,” says Joe. “We’ve learned that the best tech transfers are about having the commitment and agility to build what’s needed. When a client came to Lannett requiring blister packaging technology we didn’t yet have, we made it happen in six months. That’s the difference between a vendor and a true partner.”
The Hidden Variable: Alignment
While technology and infrastructure are critical, they’re rarely the deciding factor in tech transfer success. Without alignment, even the most advanced facilities struggle to deliver predictable results.
The CDMOs that consistently deliver on schedule are masters of communication, not just manufacturing. Clear roles, shared objectives, disciplined decision-making, and open communication across stakeholders create the conditions for execution excellence.
“People assume tech transfer is primarily a technical exercise, but it’s fundamentally a human one,” Joe observes. “The expertise of your team, the quality of communication, the willingness to innovate—these soft factors determine hard outcomes like timeline adherence and cost control.”
What to Expect from a Modern CDMO Partner
To succeed in today’s rapidly evolving and unpredictable landscape of reshoring and escalating tariffs, pharma sponsors need more than capacity. They need partners who think ahead, adapt quickly, and execute with discipline.
A modern CDMO tech transfer partner should offer proven experience across development and commercial scales, the agility to build or enhance capabilities as programs evolve, strong project management frameworks, a commitment to cost efficiency without compromising quality, and systems that enable real-time insight and continuous optimization.
When tech transfer is approached as a strategic capability rather than a transactional step, it becomes a foundation for long-term manufacturing success—not a recurring bottleneck.
